Briefing: How NAFTA/Trade Policy Proposals Undermine Trump Administration Drug Pricing Blueprint @accessiblemeds
Briefing: How NAFTA/Trade Policy Proposals Undermine Trump Administration Drug Pricing Blueprint  @accessiblemeds
Uploaded September 2018 | Updated November 2026, 3 hours ago
The U.S. is actively negotiating with Mexico and Canada to revise the North American Free Trade Agreement (NAFTA). Provisions under discussion would increase brand-name drug exclusivity (monopolies). Imposing additional brand-name drug exclusivity would keep already high brand drug prices out of reach for patients for longer.

Patients continue to pay skyrocketing brand drug prices as access to more affordable generics is delayed and the emerging biosimilars market in the U.S. is undermined.

Competition is a proven solution lower drug prices. When patients are able to access more-affordable generics and biosimilars, experience shows significant cost savings at the pharmacy counter.

However, far too often, trade agreements are used as an opportunity to export the policies that keep drug prices high in the U.S. to other countries. And a new NAFTA may be the latest attempt. Concern about the inclusion of additional brand-name drug exclusivity in NAFTA is widespread.
Learn more at: bit.ly/NewNAFTA
Briefing: How NAFTA/Trade Policy Proposals Undermine Trump Administration Drug Pricing BlueprintAAM Lifetime Achievement Award - Joe RennerJoin us a GRx+Biosims 2021 — Progress + ProcessAAM Lifetime Achievement Award at Access! 2022GRx+Biosims 2022Christine Simmon: Policy and Biosimilars Sessions at the GRx+Biosims 2020 Virtual ConferencePatient Perspective on the Value of Biosimilars During IGBA #GlobalBiosimilarsWeekGeneric Drugs Are the Prescription for Savings. Dont Take Them for Granted.The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMedsMessage from CEO Dan Leonard on Access! 2021AAM All Access Promo: Mary Beth PowersGeneric Rx Drugs: Take With Confidence (Jonnie)
Association for Accessible Medicines |

Briefing: How NAFTA/Trade Policy Proposals Undermine Trump Administration Drug Pricing Blueprint

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER